Loading stock data…
Cogent Biosciences (COGT)
$38.74+0.64 (+1.68%)
After Hours$38.74+0.00 (+0.00%)· Last close Jun 29
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cogent Biosciences, Inc. in the Healthcare sector is trading at $38.74 with a market capitalization of $5.6B. Wall Street consensus targets $54.25 (12 analysts), implying a +40.0% move over the next 12 months. The stock is currently near its 52-week high of $43.73, remaining 21.7% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +40.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$103.61M↓ | -$99.49M↓ | -$83.36M↓ | -$75.58M↓ | -$74.93M |
| Net Income | -$97.35M↑ | -$102.49M↓ | -$80.93M↓ | -$73.53M↓ | -$71.99M |
Peer Comparison
JNJUNHPFE
Fundamentals
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.57B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-58.30%
Volume
Today's trading volume
3.19M
Recent News
Is Cogent Biosciences (COGT) ’s New Cancer Drug 100 Times More Precise Than What’s Already on the Market?
Cogent Biosciences, Inc. (NASDAQ:COGT) is one of the most promising healthcare stocks according to Wall Street analysts. On June 12, Cogent Biosciences, Inc. (NASDAQ:COGT) presented early-stage preclinical data for its experimental drug CGT1145 at the European Hematology Association Congress in Stockholm, Sweden. The company presented the drug candidate as a potentially more precise and better-tolerated […]
Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trial
Cogent Biosciences (COGT) Bezuclastinib showed "rapid and deep" clinical benefit and met primary and
How Investors May Respond To Cogent Biosciences (COGT) Priority Review For Bezuclastinib GIST Regimen
Cogent Biosciences recently reported detailed primary analysis data from its PEAK Phase 3 trial, showing that bezuclastinib plus sunitinib significantly improved progression-free survival and objective response rates versus sunitinib alone in previously imatinib-treated GIST patients, with a safety profile consistent with known sunitinib risks. The combination has received FDA Priority Review with a November 30, 2026 PDUFA date, and Cogent has already launched new first-line GIST studies and...
Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy Now?
Is COGT a good stock to buy? We came across a bullish thesis on Cogent Biosciences, Inc. on X.com by @seedy19tron. In this article, we will summarize the bulls’ thesis on COGT. Cogent Biosciences, Inc.’s share was trading at $34.81 as of June 1st. Cogent Biosciences (COGT) is a clinical-stage oncology company focused on KIT mutation-driven diseases, […]
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter
This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disorders via its PRISM platform.